Immunovant, Inc.
IMVT
$22.71
$0.693.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -32.70% | 29.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.57% | 11.77% | |||
| Operating Income | -3.57% | -11.77% | |||
| Income Before Tax | -5.19% | -13.07% | |||
| Income Tax Expenses | -34.94% | 56.60% | |||
| Earnings from Continuing Operations | -4.88% | -13.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.88% | -13.31% | |||
| EBIT | -3.57% | -11.77% | |||
| EBITDA | -3.57% | -11.78% | |||
| EPS Basic | -3.20% | -10.57% | |||
| Normalized Basic EPS | -3.52% | -10.33% | |||
| EPS Diluted | -3.20% | -10.57% | |||
| Normalized Diluted EPS | -3.52% | -10.33% | |||
| Average Basic Shares Outstanding | 1.62% | 2.48% | |||
| Average Diluted Shares Outstanding | 1.62% | 2.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||